NEJM.org
@nejm.org
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.
Follow @ai.nejm.org for medical AI content.
Follow @ai.nejm.org for medical AI content.
Pinned
What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation?
View the full results of the AQUATIC trial: nej.md/45AU4Wp
#MedSky #CardioSky
View the full results of the AQUATIC trial: nej.md/45AU4Wp
#MedSky #CardioSky
In patients with cardiovascular disease and an implantable cardioverter–defibrillator, increasing potassium levels to the high-normal range reduced the risk of arrhythmia events, hospitalizations, and death. Full POTCAST trial results and Research Summary: nej.md/4oQtHTN
#MedSky
#MedSky
November 25, 2025 at 2:13 PM
In patients with cardiovascular disease and an implantable cardioverter–defibrillator, increasing potassium levels to the high-normal range reduced the risk of arrhythmia events, hospitalizations, and death. Full POTCAST trial results and Research Summary: nej.md/4oQtHTN
#MedSky
#MedSky
For a man hospitalized for uncomplicated diverticulitis who is found to have high blood pressure, would you support watchful waiting or recommend inpatient treatment of the high blood pressure? Read the case vignette, treatment options, and vote: nej.md/485a82I
November 24, 2025 at 8:06 PM
For a man hospitalized for uncomplicated diverticulitis who is found to have high blood pressure, would you support watchful waiting or recommend inpatient treatment of the high blood pressure? Read the case vignette, treatment options, and vote: nej.md/485a82I
A 75-year-old woman with a history of breast cancer treated with mastectomy of both breasts and adjuvant hormonal therapy presented with a 1-year history of a rash on her chest. Read the full case details: nej.md/47YGxI4
#MedSky #Oncology #DermSky
#MedSky #Oncology #DermSky
November 24, 2025 at 5:04 PM
A 75-year-old woman with a history of breast cancer treated with mastectomy of both breasts and adjuvant hormonal therapy presented with a 1-year history of a rash on her chest. Read the full case details: nej.md/47YGxI4
#MedSky #Oncology #DermSky
#MedSky #Oncology #DermSky
In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results and Research Summary: nej.md/45NUK9v
November 24, 2025 at 2:13 PM
In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results and Research Summary: nej.md/45NUK9v
In patients with cardiovascular disease and an implantable cardioverter–defibrillator, increasing potassium levels to the high-normal range reduced the risk of arrhythmia events, hospitalizations, and death. Full POTCAST trial results: nej.md/4oQtHTN
#MedSky #CardioSky
#MedSky #CardioSky
November 23, 2025 at 8:01 PM
In patients with cardiovascular disease and an implantable cardioverter–defibrillator, increasing potassium levels to the high-normal range reduced the risk of arrhythmia events, hospitalizations, and death. Full POTCAST trial results: nej.md/4oQtHTN
#MedSky #CardioSky
#MedSky #CardioSky
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG
November 23, 2025 at 2:00 PM
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG
📖 Further reading
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
November 22, 2025 at 8:01 PM
📖 Further reading
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
What are the challenges of recommending bisphosphonates to patients who have normal bone density? Dr. Ann Garment discusses this in the latest episode of Beyond Journal Club, a collaboration between @coreimpodcast.bsky.social and NEJM Group. Full episode: nej.md/4q7hOK3
#MedSky
#MedSky
November 22, 2025 at 8:01 PM
What are the challenges of recommending bisphosphonates to patients who have normal bone density? Dr. Ann Garment discusses this in the latest episode of Beyond Journal Club, a collaboration between @coreimpodcast.bsky.social and NEJM Group. Full episode: nej.md/4q7hOK3
#MedSky
#MedSky
Among older adults with frailty, evidence on the benefits and risks of discontinuing antihypertensive drugs is limited. Research findings from the RETREAT-FRAIL trial are summarized in a new Quick Take video. nej.md/482WnBv
#MedSky #CardioSky
#MedSky #CardioSky
November 22, 2025 at 5:02 PM
Among older adults with frailty, evidence on the benefits and risks of discontinuing antihypertensive drugs is limited. Research findings from the RETREAT-FRAIL trial are summarized in a new Quick Take video. nej.md/482WnBv
#MedSky #CardioSky
#MedSky #CardioSky
Joshua A. Boyce, MD, describes two studies implicating intestinally generated cysteinyl leukotrienes in food anaphylaxis. Learn more: nej.md/4rp7MEL
#MedSky #PedSky #Immunology
#MedSky #PedSky #Immunology
November 22, 2025 at 2:02 PM
Joshua A. Boyce, MD, describes two studies implicating intestinally generated cysteinyl leukotrienes in food anaphylaxis. Learn more: nej.md/4rp7MEL
#MedSky #PedSky #Immunology
#MedSky #PedSky #Immunology
Reposted by NEJM.org
A new NEJM paper just dropped evaluating a quadrivalent modified mRNA (modRNA) influenza vaccine in a phase 3 trial. This is the largest test yet of whether the mRNA platform that transformed COVID-19 vaccination can improve our fight against flu.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine | NEJM
Influenza remains a major health burden despite the use of licensed vaccines. Nucleoside-modified
messenger RNA (modRNA) influenza vaccines have shown promising immunogenicity against
influenza and...
www.nejm.org
November 20, 2025 at 12:26 PM
A new NEJM paper just dropped evaluating a quadrivalent modified mRNA (modRNA) influenza vaccine in a phase 3 trial. This is the largest test yet of whether the mRNA platform that transformed COVID-19 vaccination can improve our fight against flu.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
New from NEJM Catalyst Innovations in Care Delivery:
A pilot randomized controlled trial exploring the link between receiving a preferred safety device and a change in firearm-storage behavior.
Read the full article: nej.md/3JYujr2
#PublicHealth
A pilot randomized controlled trial exploring the link between receiving a preferred safety device and a change in firearm-storage behavior.
Read the full article: nej.md/3JYujr2
#PublicHealth
November 21, 2025 at 8:01 PM
New from NEJM Catalyst Innovations in Care Delivery:
A pilot randomized controlled trial exploring the link between receiving a preferred safety device and a change in firearm-storage behavior.
Read the full article: nej.md/3JYujr2
#PublicHealth
A pilot randomized controlled trial exploring the link between receiving a preferred safety device and a change in firearm-storage behavior.
Read the full article: nej.md/3JYujr2
#PublicHealth
Editorial: Managing Asymptomatic Carotid Stenosis nej.md/482XjG1
November 21, 2025 at 3:38 PM
Editorial: Managing Asymptomatic Carotid Stenosis nej.md/482XjG1
Presented at #SVIN25:
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
November 21, 2025 at 3:38 PM
Presented at #SVIN25:
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
In patients with cardiovascular disease and low or low-normal potassium levels, whether increasing levels to the high-normal range lowers the risk for ventricular arrhythmias is unclear. Research findings from the POTCAST trial are summarized in a new Quick Take video. nej.md/49JTckP
November 21, 2025 at 2:23 PM
In patients with cardiovascular disease and low or low-normal potassium levels, whether increasing levels to the high-normal range lowers the risk for ventricular arrhythmias is unclear. Research findings from the POTCAST trial are summarized in a new Quick Take video. nej.md/49JTckP
Listen to the latest episode, “Undervalued,” as well as past episodes, and subscribe to the podcast: nej.md/NOS
November 20, 2025 at 8:35 PM
Listen to the latest episode, “Undervalued,” as well as past episodes, and subscribe to the podcast: nej.md/NOS
Hear more from Dr. Clarkson in “If You Break It, They Won't Come,” episode 3.4 of the Not Otherwise Specified podcast, hosted by NEJM National Correspondent Dr. Lisa Rosenbaum: nej.md/4oPRtyl
November 20, 2025 at 8:35 PM
Hear more from Dr. Clarkson in “If You Break It, They Won't Come,” episode 3.4 of the Not Otherwise Specified podcast, hosted by NEJM National Correspondent Dr. Lisa Rosenbaum: nej.md/4oPRtyl
Dr. Wright Clarkson, a family medicine resident at Virginia Mason Franciscan Health in Washington, shares how microaggressions and attitudes toward primary care physicians shaped his experience as a medical student.
November 20, 2025 at 8:35 PM
Dr. Wright Clarkson, a family medicine resident at Virginia Mason Franciscan Health in Washington, shares how microaggressions and attitudes toward primary care physicians shaped his experience as a medical student.
Case Record of the Massachusetts General Hospital: A 27-year-old man with bipolar I disorder was admitted to the hospital with abnormal behaviors and confusion. Tachycardia was present, and the patient had a seizure. A diagnosis was made. Read the full case details: nej.md/4oGQxg8
November 20, 2025 at 5:01 PM
Case Record of the Massachusetts General Hospital: A 27-year-old man with bipolar I disorder was admitted to the hospital with abnormal behaviors and confusion. Tachycardia was present, and the patient had a seizure. A diagnosis was made. Read the full case details: nej.md/4oGQxg8
Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) nej.md/43udoTG
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 20, 2025 at 2:06 PM
Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) nej.md/43udoTG
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
New in the November 20, 2025, issue of NEJM:
Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) nej.md/4oQtHTN
Reducing Antihypertensive Drugs in Nursing Home Residents (RETREAT-FRAIL trial) nej.md/45NUK9v
#MedSky
Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) nej.md/4oQtHTN
Reducing Antihypertensive Drugs in Nursing Home Residents (RETREAT-FRAIL trial) nej.md/45NUK9v
#MedSky
November 20, 2025 at 2:06 PM
New in the November 20, 2025, issue of NEJM:
Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) nej.md/4oQtHTN
Reducing Antihypertensive Drugs in Nursing Home Residents (RETREAT-FRAIL trial) nej.md/45NUK9v
#MedSky
Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) nej.md/4oQtHTN
Reducing Antihypertensive Drugs in Nursing Home Residents (RETREAT-FRAIL trial) nej.md/45NUK9v
#MedSky
A new review summarizes the genetics, diagnosis, and treatment of long QT syndrome, a major cause of sudden death in young people. Risk stratification and genotype-guided therapy are essential. Learn more in a new Review Article: nej.md/44cxXnN
#MedSky #CardioSky
#MedSky #CardioSky
November 19, 2025 at 11:01 PM
A new review summarizes the genetics, diagnosis, and treatment of long QT syndrome, a major cause of sudden death in young people. Risk stratification and genotype-guided therapy are essential. Learn more in a new Review Article: nej.md/44cxXnN
#MedSky #CardioSky
#MedSky #CardioSky
Editorial: An Early Look at mRNA Vaccines to Prevent Influenza nej.md/488N2Z3
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
November 19, 2025 at 10:40 PM
Editorial: An Early Look at mRNA Vaccines to Prevent Influenza nej.md/488N2Z3
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results: nej.md/43udoTG
#MedSky #IDSky
#MedSky #IDSky
November 19, 2025 at 10:40 PM
Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results: nej.md/43udoTG
#MedSky #IDSky
#MedSky #IDSky
This cluster-randomized trial in Malawi and Uganda showed a significant benefit of an intervention to support health care providers in hand washing, preventing and managing maternal infection, and detecting and treating sepsis. Full APT-Sepsis trial results: nej.md/4o6xhaF
#MedSky #OBGYN
#MedSky #OBGYN
November 19, 2025 at 10:10 PM
This cluster-randomized trial in Malawi and Uganda showed a significant benefit of an intervention to support health care providers in hand washing, preventing and managing maternal infection, and detecting and treating sepsis. Full APT-Sepsis trial results: nej.md/4o6xhaF
#MedSky #OBGYN
#MedSky #OBGYN